A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

NCT06916793 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

288

Enrollment

INDUSTRY

Sponsor class

Conditions

Androgenetic Alopecia

Interventions

DRUG: CKD-843 dose#1
DRUG: CKD-843 dose#2
DRUG: Placebo of CKD-843 dose
DRUG: Dutasteride Capsules
DRUG: Placebo of Dutasteride Capsule

Sponsor

Chong Kun Dang Pharmaceutical